GSK plc

GSK plc Forward P/E

The Forward P/E Ratio of GSK plc (GSK.L) as of Nov 3, 2026 is 15.28. In the previous year, Forward P/E Ratio was 33.92 — a change of -54.95% (lower).

Forward P/E

15.28

YoY

-54.95%

Last updated:

Forward P/E Ratio of GSK plc is 2025 15.28 . Forward P/E Ratio of GSK plc was 2024 33.92 . It decreases by -54.95% lower compared to the previous year.

The GSK plc Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
24.11 GBP
Jan 1, 2019
18.81 GBP
Jan 1, 2020
15.19 GBP
Jan 1, 2021
19.92 GBP
Jan 1, 2022
5.84 GBP
Jan 1, 2023
17.73 GBP
Jan 1, 2024
33.92 GBP
Jan 1, 2025
15.28 GBP
The GSK plc Forward P/E history
YEARForward P/EYoY
15.28-54.95%
33.92+91.38%
17.73+203.49%
5.84-70.68%
19.92+31.11%
15.19-19.20%
18.81-22.00%
24.11-57.71%
57.02-40.47%
95.78+823.46%
10.37-67.28%
31.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Forward P/E Ratio of GSK plc is 15.28 in 2025.

Forward P/E Ratio of GSK plc changed from 33.92 to 15.28, representing a -54.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio GSK plc since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GSK plc

All Key Metrics — GSK plc